AR058199A1 - Derivados de 3- alquilazetidina sustituidos con heterociclos - Google Patents

Derivados de 3- alquilazetidina sustituidos con heterociclos

Info

Publication number
AR058199A1
AR058199A1 ARP060105076A ARP060105076A AR058199A1 AR 058199 A1 AR058199 A1 AR 058199A1 AR P060105076 A ARP060105076 A AR P060105076A AR P060105076 A ARP060105076 A AR P060105076A AR 058199 A1 AR058199 A1 AR 058199A1
Authority
AR
Argentina
Prior art keywords
treatment
disorders
methyl
independently selected
cyano
Prior art date
Application number
ARP060105076A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of AR058199A1 publication Critical patent/AR058199A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

Son antagonistas y/o agonistas inversos del receptor canabinoide-1 (CB1) y son utiles en el tratamiento, prevencion y supresion de enfermedades mediadas por el receptor CB1. Los compuestos de la presente son utiles como fármacos que actuan a nivel central en el tratamiento de psicosis, deficiencias de la memoria, trastornos cognitivos, enfermedad de Alzheimer, migrana, neuropatía, trastornos neuroinflamatorios que incluyen esclerosis multiple y síndrome de Guillain-Barré y las secuelas inflamatorias de la encefalitis vírica, accidentes vasculares cerebrales, y traumatismo craneal, trastornos de ansiedad, estrés, epilepsia, enfermedad de Parkinson, trastornos del movimiento, y esquizofrenia. Los compuestos también son utiles para el tratamiento de trastornos de abuso de sustancias, para el tratamiento de obesidad o trastornos de la alimentacion, así como para el tratamiento de asma, estrenimiento, pseudo-obstruccion intestinal cronica, y cirrosis hepática. Reivindicacion 1: Un compuesto de la formula estructural (1) en el que: X se selecciona de: hidroxi, NH2, metilo, y metoxi; R2 y R3 cada uno se selecciona independientemente de: H, metilo, F, hidroxilo, y trifluorometilo; con la condicion de que R2 y R3 no sean ambos H cuando X es hidroxi, -NH2, o metoxi; R8 se selecciona de: R15, H, halogeno, metilo, -CF3, ciano, y SO2CH3; R9 se selecciona de: R15, H, F, Cl, y ciano; R10 se selecciona de R15, H, F, Cl, -CF3, ciano y metilo; con la condicion de que al menos uno de R8, R9, y R10 sea R15; cada R15 es un anillo heterocíclico insaturado de 5 miembros que se selecciona de entre el grupo de formulas (2); cada Rh se selecciona independientemente de: -H, -OH, -SH, -NH2, alquilo C1-3, y -CF3; cada Ri se selecciona independientemente de: -H, -OH, -SH, -NH2, alquilo C1-3, y -CF3; cada Rk se selecciona independientemente de: -H y alquilo C1-3; n se selecciona de 0, 1 y 2, o una sal o solvato farmacéuticamente aceptable del mismo.
ARP060105076A 2005-11-28 2006-11-20 Derivados de 3- alquilazetidina sustituidos con heterociclos AR058199A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74018305P 2005-11-28 2005-11-28

Publications (1)

Publication Number Publication Date
AR058199A1 true AR058199A1 (es) 2008-01-23

Family

ID=37779312

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105076A AR058199A1 (es) 2005-11-28 2006-11-20 Derivados de 3- alquilazetidina sustituidos con heterociclos

Country Status (15)

Country Link
EP (1) EP1954692A1 (es)
KR (1) KR20080073721A (es)
AR (1) AR058199A1 (es)
BR (1) BRPI0619018A2 (es)
CR (1) CR10014A (es)
DO (1) DOP2006000261A (es)
EC (1) ECSP088477A (es)
IL (1) IL191586A0 (es)
MA (1) MA30086B1 (es)
NO (1) NO20082919L (es)
PE (1) PE20070647A1 (es)
RU (1) RU2008126248A (es)
SV (1) SV2009002917A (es)
TW (1) TW200804317A (es)
WO (1) WO2007062193A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906652B2 (en) * 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU2008317482A1 (en) * 2007-10-24 2009-04-30 Merck Sharp & Dohme Corp. Synthesis and crystalline forms of CB-1 antagonist/inverse agonist
WO2012031220A2 (en) 2010-09-03 2012-03-08 University Of Florida Research Foundation, Inc. Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2805818B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
FR2805817B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
FR2805810B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
BRPI0411131A (pt) * 2003-06-11 2006-07-18 Merck & Co Inc composto, método de tratar uma doença mediada pelo receptor de canabinóide 1, método de previnir a obesidade de uma pessoa com risco de obesidade, composição, e, uso de um composto
US20090306037A1 (en) * 2005-05-02 2009-12-10 Merck & Co., Inc. Combination of a Dipeptidyl Peptidase-IV Inhibitor and a Cannabinoid CB1 Receptor Antagonist for the Treatment of Diabetes and Obesity

Also Published As

Publication number Publication date
MA30086B1 (fr) 2008-12-01
CR10014A (es) 2008-07-29
EP1954692A1 (en) 2008-08-13
WO2007062193A1 (en) 2007-05-31
RU2008126248A (ru) 2010-01-10
SV2009002917A (es) 2009-02-19
BRPI0619018A2 (pt) 2016-11-29
NO20082919L (no) 2008-08-27
TW200804317A (en) 2008-01-16
DOP2006000261A (es) 2007-07-15
IL191586A0 (en) 2008-12-29
PE20070647A1 (es) 2007-08-11
KR20080073721A (ko) 2008-08-11
ECSP088477A (es) 2008-06-30

Similar Documents

Publication Publication Date Title
AR058199A1 (es) Derivados de 3- alquilazetidina sustituidos con heterociclos
ATE375349T1 (de) Substituierte furo(2,3-b)pyridin derivate
JO2482B1 (en) Amide compounds by replacement
DE60334787D1 (de) Substituierte amide
JP5939254B2 (ja) ｃ−Ｍｅｔキナーゼ阻害剤としての化合物
JP2019031560A5 (es)
ECSP056207A (es) Derivados de 3-alquil y 3-alquenilazetidina sustituidos
ATE452890T1 (de) Substituierte naphthyridinonderivate
ATE501151T1 (de) Substituierte pyrano ä2, 3 - büpyridinderivate als cannabinoid-1 rezeptormodulatoren
HRP20211282T1 (hr) Oksisteroli i postupci njihovog korištenja
JP2011523412A5 (es)
AR068511A1 (es) Tetrahidro[1,4'] bipiridinil-2'-onas sustituidas, composiciones farmaceuticas que las contienen y usos de las mismas para tratar o prevenir trastornos del sistema nervioso central
AR040351A1 (es) Derivados de quinuclidina-amida, composicion farmaceutica, procedimiento de preparacion del compuesto y su uso para fabricar medicamentos
WO2004029204A3 (en) Substituted pyrimidines
WO2000075113A1 (fr) Nouveaux derives carboxamide heterocycliques
WO2008024284A3 (en) Sulfonylated piperazines as cannabinoid-1 receptor modulators
JP2004529105A5 (es)
WO2004058145A3 (en) Substituted amides
AR036191A1 (es) Compuestos antagonistas de receptores y5 del neuropeptido y, una composicion farmaceutica, un procedimiento para preparar dicha composicion y el uso de dichos compuestos, solos o en combinacion para la preparacion de una composicion farmaceutica
JP2013505948A5 (es)
WO2003086288A3 (en) Bicyclic amides
JP2017504635A5 (es)
JP2009534358A5 (es)
JP2011500621A5 (es)
JP2009541404A5 (es)

Legal Events

Date Code Title Description
FB Suspension of granting procedure